Cargando…
New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
BACKGROUND: Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656147/ https://www.ncbi.nlm.nih.gov/pubmed/34922126 http://dx.doi.org/10.1016/j.jneuroim.2021.577785 |
_version_ | 1784612223327404032 |
---|---|
author | Toljan, Karlo Amin, Moein Kunchok, Amy Ontaneda, Daniel |
author_facet | Toljan, Karlo Amin, Moein Kunchok, Amy Ontaneda, Daniel |
author_sort | Toljan, Karlo |
collection | PubMed |
description | BACKGROUND: Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case. CONCLUSION: Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis. |
format | Online Article Text |
id | pubmed-8656147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86561472021-12-09 New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure Toljan, Karlo Amin, Moein Kunchok, Amy Ontaneda, Daniel J Neuroimmunol Short Communication BACKGROUND: Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case. CONCLUSION: Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis. Elsevier B.V. 2022-01-15 2021-12-09 /pmc/articles/PMC8656147/ /pubmed/34922126 http://dx.doi.org/10.1016/j.jneuroim.2021.577785 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Toljan, Karlo Amin, Moein Kunchok, Amy Ontaneda, Daniel New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure |
title | New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure |
title_full | New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure |
title_fullStr | New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure |
title_full_unstemmed | New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure |
title_short | New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure |
title_sort | new diagnosis of multiple sclerosis in the setting of mrna covid-19 vaccine exposure |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656147/ https://www.ncbi.nlm.nih.gov/pubmed/34922126 http://dx.doi.org/10.1016/j.jneuroim.2021.577785 |
work_keys_str_mv | AT toljankarlo newdiagnosisofmultiplesclerosisinthesettingofmrnacovid19vaccineexposure AT aminmoein newdiagnosisofmultiplesclerosisinthesettingofmrnacovid19vaccineexposure AT kunchokamy newdiagnosisofmultiplesclerosisinthesettingofmrnacovid19vaccineexposure AT ontanedadaniel newdiagnosisofmultiplesclerosisinthesettingofmrnacovid19vaccineexposure |